Site icon pharmaceutical daily

Chemotherapy Induced Neutropenia Pipeline Review, H1 2019 Edition – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chemotherapy
Induced Neutropenia – Pipeline Review, H1 2019”
drug pipelines
has been added to ResearchAndMarkets.com’s offering.

Chemotherapy
Induced Neutropenia – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Chemotherapy
Induced Neutropenia (Toxicology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The
Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also
reviews of key players involved in therapeutic development for
Chemotherapy Induced Neutropenia and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase
I and Preclinical stages are 5, 1, 5, 8, 6 and 8 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.

Chemotherapy Induced Neutropenia
(Toxicology) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.

Scope:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3wxh75/chemotherapy?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs

Exit mobile version